Lucas Michel Todó
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lucas Michel Todó has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Abel González-Pérez
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain
48 shared publications - Alexander William Wyatt
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
48 shared publications - Anna Oliveira Tercero
10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, Barcelona, Spain
48 shared publications - Aslı D. Munzur
Vancouver Prostate Centre Department of Urologic Sciences University of British Columbia British Columbia Canada
48 shared publications - Chen Weller
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
48 shared publications - Claudia Arnedo-Pac
Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK
48 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity and cross reactivity of CD8+ T transduced with specific AR H875Y TCRs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity and cross reactivity of CD8+ T transduced with specific AR H875Y TCRs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Single Cell TCRseq of donor 157 with AR H875Y 9-mer dextramer staining sorted T-cells
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Single Cell TCRseq of donor 157 with AR H875Y 9-mer dextramer staining sorted T-cells
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Synthetic peptides used in this study
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Synthetic peptides used in this study
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y T157.2 TCR reactivity in healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y T157.2 TCR reactivity in healthy donor PBMCs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-A*01:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-A*01:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Distribution of cancer types and metastatic locations in the Hartwig cohort
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Distribution of cancer types and metastatic locations in the Hartwig cohort
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
MS/MS spectra for resistant gene-derived peptides and the corresponding head-to-tail analysis.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
MS/MS spectra for resistant gene-derived peptides and the corresponding head-to-tail analysis.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity gating strategy of reactive CD8+ T-cells derived from healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity gating strategy of reactive CD8+ T-cells derived from healthy donor PBMCs